BUTYLENE GLYCOL

Molecular Excipient

Mwt. LogP HBD HBA PSA RB CSP3
90.0 -0.3 2 2 40.0 2 1.0
CAS
107880
UNII
3XUS85K0RA
SYNONYMS
ZINC ID(s)
Availability
Present in 58 ZINC catalogs

Known Active Genes

There has not been any activity reported at 10μM or less for this excipient (per ChEBML)

Clinical Trials

This compound has been an intervention in the following clincial trials (per clinicaltrials.gov).
Code Date Title Phase Status
NCT02390063 2015-03-01 VAccination in Prostate caNCEr (VANCE) Phase 1 Not Yet Recruiting
NCT02196077 2014-08-01 Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Phase 2 Active, Not Recruiting
NCT02105012 2014-04-01 Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma Phase 2 Recruiting
NCT02114320 2014-03-01 Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents Phase 3 Completed
NCT02009956 2014-02-01 EXCELLA Post-Approval Study Phase 4 Active, Not Recruiting
NCT01645696 2012-06-01 Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics Phase 1/Phase 2 Completed
NCT01557907 2012-02-01 Multi-day (3) In-patient Evaluation of Intradermal Versus Subcutaneous Basal and Bolus Insulin Infusion Phase 1/Phase 2 Completed
NCT01120444 2010-04-01 Study on the Effects on Blood Glucose Following Intradermal and Subcutaneous Dosing of Insulin in Diabetic Patients Phase 1/Phase 2 Completed
NCT01061216 2010-01-01 Pharmacokinetics/Dynamics of Basal (Continuous) Insulin Infusion Administered Either Intradermally or Subcutaneously Phase 1/Phase 2 Completed
NCT00980200 2009-09-01 Efficacy and Safety Study in Subjects With Asthma Phase 2 Completed
NCT00821626 2009-01-01 Rapid Flu Tests in Travelers With Fever Phase 4 Active, Not Recruiting
NCT01093833 2009-01-01 A Comparison Study of Prototype Continuous Glucose Sensors in the Intradermal and Subcutaneous Spaces Phase 1 Completed
NCT00792753 2008-10-01 "Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study ""EXCELLA II STUDY""" Phase 2/Phase 3 Active, Not Recruiting
NCT00440687 2001-01-01 Withdrawal of Inhaled Corticosteroids in Patients With COPD in Primary Care Phase 4 Completed

(Browse) Purchasable Analogs in ZINC

Dosages

Route Formulation Per Unit Dose
Topical Patch, Controlled Release
Transdermal Film, Controlled Release 8.12MG
Transdermal Patch, Controlled Release 2.03MG

More Information

Usage Over Time

Comments